Abilify Manufacturing Site Withdrawn In Response To "Approvable" Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb withdrew its proposed finished dosage manufacturing facility for Abilify in Mayaguez, Puerto Rico, six weeks before approval of the antipsychotic.
You may also be interested in...
Bristol Revisiting Abilify Bipolar Mania Indication, With Filing By Year-End
Bristol-Myers Squibb and Otsuka will take their second stab at an Abilify indication for bipolar mania via an sNDA submission before the end of 2003.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011